Literature DB >> 26907578

Association of MMPs and TIMPs With the Occurrence of Atrial Fibrillation: A Systematic Review and Meta-analysis.

Yuan Liu1, Bin Xu1, Na Wu1, Ying Xiang1, Long Wu1, Mengxuan Zhang1, Jiehua Wang1, Xinghua Chen2, Yafei Li1, Li Zhong3.   

Abstract

BACKGROUND: The roles of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in the occurrence of atrial fibrillation (AF) remain inconclusive.
METHODS: We conducted a systematic review and meta-analysis of observational studies to evaluate the associations of MMPs and TIMPs in blood and atrial tissues with AF risk. A subgroup analysis was performed to explore the potential sources of heterogeneity.
RESULTS: A total of 33 studies met our inclusion criteria. Patients with AF had significantly higher messenger RNA (mRNA) levels of MMP-1 in atrial tissue than did the controls, with a pooled standardized mean difference (SMD) of 0.54 (95% confidence interval [CI], 0.30-0.78; P < 0.001). The positive pooled estimates of studies of MMP-2 and MMP-9 in circulating proteins and atrial tissue mRNA and proteins were likely to be susceptible to the effects of significant publication bias. Decreased circulating TIMP-2 levels were significantly associated with increased risk of AF, with a pooled SMD of -0.49 (95% CI, -0.97 to -0.01; P = 0.04).
CONCLUSIONS: Increased MMP-1 in tissue mRNA and decreased circulating TIMP-2 levels are significantly associated with increased AF risk. The positive associations of MMP-2 and MMP-9 in blood and atrial tissue with AF risk have significant publication bias. Prospective registries of biomarker research and strict confirmation to reporting guidelines are needed in this field.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26907578     DOI: 10.1016/j.cjca.2015.08.001

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

1.  Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study).

Authors:  Faye L Norby; Weihong Tang; James S Pankow; Pamela L Lutsey; Alvaro Alonso; Brian Steffan; Lin Y Chen; Michael Zhang; Nathan D Shippee; Christie M Ballantyne; Eric Boerwinkle; Josef Coresh; Aaron R Folsom
Journal:  Am J Cardiol       Date:  2021-12-15       Impact factor: 3.133

Review 2.  Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).

Authors:  Loganathan Rangasamy; Bruno Di Geronimo; Irene Ortín; Claire Coderch; José María Zapico; Ana Ramos; Beatriz de Pascual-Teresa
Journal:  Molecules       Date:  2019-08-16       Impact factor: 4.411

3.  Atrial fibrosis underlying atrial fibrillation (Review).

Authors:  Chang Yi Li; Jing Rui Zhang; Wan Ning Hu; Song Nan Li
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

4.  Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study.

Authors:  Elena Palà; Alejandro Bustamante; Josep Lluis Clúa-Espuny; Juan Acosta; Felipe González-Loyola; Sara Dos Santos; Domingo Ribas-Segui; Juan Ballesta-Ors; Anna Penalba; Marina Giralt; Iñigo Lechuga-Duran; Delicia Gentille-Lorente; Alonso Pedrote; Miguel Ángel Muñoz; Joan Montaner
Journal:  PLoS One       Date:  2022-08-23       Impact factor: 3.752

5.  Adhesion pathway proteins and risk of atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Israel J Mendez; Sheila M Manemann; Elizabeth J Bell; Nicholas B Larson; Paul A Decker; Marco A Guerrero; Naomi Q Hanson; Susan R Heckbert; James S Pankow; Michael Y Tsai; Suzette J Bielinski
Journal:  BMC Cardiovasc Disord       Date:  2021-09-14       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.